Update on the 2022 Rare Disease Day!

This year’s Rare Disease Day was a resounding success! Thank you to many of you for participating with the Zebra-themed shirts and jean ribbons, for joining the virtual event and for various activities you have conducted to raise awareness on rare diseases.  If you missed the wonderful virtual event organized by our friends at NORD,…

Read More

Community Spotlight: Ashley Harris

Meet Ashley Harris, APS Type 1 mom and administrator of the Foundation’s Community Facebook page for friends and families with APS Type 1. “Originally from San Antonio, TX, and currently living in Washington, D.C., my husband, Dave, and I met at the University of Alabama (Roll Tide) and have been living an adventurous and chaotic military life…

Read More

NATPARA® Update

NATPARA® Update Pharmaceutical company Takeda continues to work with the U.S. Food and Drug Administration (FDA) to bring NATPARA® back on the market.  Unfortunately, there is more work to do.   Click on the link below to read Takeda’s recent regulatory update.  According to the update, Takeda plans to continue providing NATPARA® to those enrolled in its…

Read More

#RAREis Scholarship Fund

Pursue Your Dreams through the #RAREis Scholarship Fund The #RAREis Scholarship Fund was established in 2020 to help young adults with rare diseases to pursue their dreams through education. Thanks to the support of the #RAREis program by Horizon Therapeutics, The EveryLife Foundation is pleased to announce its third year of the #RAREis Scholarship Fund, a scholarship dedicated to the…

Read More

SAVE THE DATES: IDF x APS Type 1 Get Connected Series 2022

In partnership with the IDF (Immune Deficiency Foundation), we are planning a regular virtual get-together for our patient community, so that we can connect with other families and medical professionals in the APS Type 1 field! The virtual platform via Zoom allows us to meet and ask questions, share tips, and bond together with community…

Read More

The RARE Compassion Program (Community News)

It is estimated that 30 million people in the United States, or 1 in 10, are living with a rare medical condition. Although understanding the experience of a person with a rare disease can enable improved health, faster and more accurate diagnosis, and better care for individuals and families living with rare diseases, medical professionals…

Read More

A Rare Disease Day Toolkit! >> Feb 28, 2022

DO YOU KNOW A STUDENT WHO IS INTERESTED IN RAISING AWARENESS? February 28 (the rarest last day of the year) marks World Rare Disease Day.  Julia Band Orange and Julia Finch have compiled materials to create a “Rare Disease Day In-a-Box”!  Please click here to find an awareness video, a sample speech, an article for a school…

Read More
Breaking Down Common Terms in the Immune Deficiency Space

Breaking Down Common Terms in the Immune Deficiency Space

As with any medical field, there are a number of terms in the immunodeficiency community that can quickly get confusing for new patients and their caregivers. A few examples: immunocompromised, immunosuppressed, primary immunodeficiency, secondary (or acquired) immunodeficiency, inborn errors of immunity. What do these terms mean? And how do they relate to each other? Defining…

Read More

FDA APPROVES ANTIVIRAL PILLS TO TREAT COVID-19 AT HOME

The Food and Drug Administration announced an emergency use authorization (EUA) of antiviral treatments for mild-to-moderate coronavirus disease (Covid-19) on December 22 and 23rd. This wonderful news provides a useful new course of action for covid-19 infections, including breakthrough cases of omicron as well as the other variants. These antiviral treatments will eventually be for…

Read More

The NIH’s COVID-19 Treatment Guidelines Panel Issues Updated Statement on Therapies for High-Risk, Nonhospitalized Patients with Mild to Moderate COVID-19

On December 22 and 23, 2021, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) that allow 2 new oral antiviral agents to be used in this patient population: ritonavir-boosted nirmatrelvir (Paxlovid) and molnupiravir.   The NIH’s COVID-19 Treatment Guidelines Panel issued an updated statement today to provide clinicians with guidance on the…

Read More